LeMaitre Vascular Stock Price, News & Analysis (NASDAQ:LMAT)

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for LeMaitre Vascular in the last twelve months. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" LMAT shares.
View LMAT analyst ratings or view top-rated stocks.

6 Wall Street research analysts have issued 1-year target prices for LeMaitre Vascular's stock. Their LMAT share price targets range from $60.00 to $75.00. On average, they anticipate the company's stock price to reach $67.60 in the next twelve months. This suggests a possible upside of 24.8% from the stock's current price.
View analysts price targets for LMAT or view top-rated stocks among Wall Street analysts.

LeMaitre Vascular's stock was trading at $46.02 at the beginning of the year. Since then, LMAT stock has increased by 17.7% and is now trading at $54.17.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024.
View our LMAT earnings forecast.

LeMaitre Vascular, Inc. (NASDAQ:LMAT) issued its quarterly earnings results on Wednesday, November, 1st. The medical instruments supplier reported $0.33 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.31 by $0.02. The medical instruments supplier had revenue of $47.40 million for the quarter, compared to analysts' expectations of $47.58 million. LeMaitre Vascular had a trailing twelve-month return on equity of 9.83% and a net margin of 14.69%. The firm's revenue was up 21.5% compared to the same quarter last year. During the same quarter last year, the firm earned $0.25 EPS.

LeMaitre Vascular announced a quarterly dividend on Tuesday, October 24th. Stockholders of record on Thursday, November 16th will be paid a dividend of $0.14 per share on Thursday, November 30th. This represents a $0.56 annualized dividend and a yield of 1.03%. The ex-dividend date of this dividend is Wednesday, November 15th.
Read our dividend analysis for LMAT.

LeMaitre Vascular (NASDAQ:LMAT) pays an annual dividend of $0.56 per share and currently has a dividend yield of 1.04%. The company has been increasing its dividend for 12 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 46.28%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, LMAT will have a dividend payout ratio of 36.36% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for LMAT.

ETFs with the largest weight of LeMaitre Vascular (NASDAQ:LMAT) stock in their portfolio include Pacer US Small Cap Cash Cows Growth Leaders ETF (CAFG), Invesco S&P SmallCap Health Care ETF (PSCH) and iShares Micro-Cap ETF (IWC).iShares U.S. Medical Devices ETF (IHI).

LeMaitre Vascular issued an update on its FY23 earnings guidance on Wednesday, November, 1st. The company provided earnings per share guidance of $1.30-1.35 for the period, compared to the consensus earnings per share estimate of $1.28. The company issued revenue guidance of $192.6-194.6 million, compared to the consensus revenue estimate of $195.01 million.

13 employees have rated LeMaitre Vascular Chief Executive Officer George W. LeMaitre on Glassdoor.com. George W. LeMaitre has an approval rating of 33% among the company's employees. This puts George W. LeMaitre in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other LeMaitre Vascular investors own include AbbVie (ABBV), Sociedad Química y Minera de Chile (SQM), Gilead Sciences (GILD), Aurora Cannabis (ACB), Aurora Cannabis (ACBFF), NVIDIA (NVDA), Adobe (ADBE), Boeing (BA) and Salesforce (CRM).

LeMaitre Vascular's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Conestoga Capital Advisors LLC (8.61%), Copeland Capital Management LLC (5.53%), Ranger Investment Management L.P. (4.04%), Congress Asset Management Co. MA (2.28%), Northern Trust Corp (1.37%) and Ameriprise Financial Inc. (1.18%). Insiders that own company stock include Bridget A Ross, David B Roberts, George W Lemaitre, George W Lemaitre, John A Roush, Joseph P Pellegrino Jr, Lawrence J Jasinski and Trent G Kamke.
View institutional ownership trends.

Shares of LMAT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.